FDA Announces Joint Meeting of Advisory Committees to Discuss Cardiovascular and Renal Drugs, as well as Drug Safety and Risk Management

Summary

The US Food and Drug Administration (FDA) has scheduled a joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee to discuss various topics related to cardiovascular and renal drugs, as well as drug safety and risk management, which is expected to take place recently.